ArticleCurrent radiopharmaceuticals2025
Real-world Data on Intermediate-risk Differentiated Thyroid Cancer Biochemical Response to 3700 or 5550 MBq of [
Article in Current radiopharmaceuticals, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe ideal [
methodsA retrospective study was conducted by reviewing the medical records of intermediaterisk thyroid cancer patients who received RIT between 2016 and 2020 at a reference cancer hospital in Brazil. Sociodemographic and clinical data were evaluated at the time of diagnosis. Clinical data during two years of follow-up were reviewed, and biochemical responses were determined according to the American Thyroid Association (ATA, 2015 version). Responses to doses of 3700 MBq (100 mCi) and 5550 MBq (150 mCi) of [
resultsNo significant statistical differences were observed concerning the biochemical therapeutic responses of patients treated with 3700 MBq or 5550 MBq (p = 0.088). The presence of nodal metastasis and positive pre-RIT thyroglobulin did not influence biochemical responses to radioiodine. DISCUSSION: According to ATA 2015 guidelines, RIT may be administered to patients classified at intermediate risk for the ablation of post-surgical tissue remnants, as well as an adjuvant treatment for potential persistent tumor foci and to reduce recurrence risks. These recommendations, however, do not specify the appropriate radioiodine dosage and this has been a topic of extensive debate.
conclusionIntermediate risk thyroid-cancer patients presented similar therapeutic responses to the doses of 3700 MBq and 5550 MBq [
Indexed as
Identifiers
40329734What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.